Efficacy of tiotropium bromide inhalation powder combined with salmeterol/fluticasone in the treatment of elderly patients with asthma-COPD overlap syndrome
Objective To observe the clinical efficacy of tiotropium bromide inhalation powder combined with salmeterol/flu-ticasone in treating elderly patients with asthma-COPD overlap syndrome(ACOS).Methods A total of 96 ACOS patients treated at our hospital between March 2019 and March 2022 were randomly allocated to observation and control groups,with 48 cases in each.The control group was treated with salmeterol/fluticasone alone,while the observation group received tiotropium bromide inhalation powder combined with salmeterol/fluticasone for a course of 3 months.Clinical efficacy,acute exacerbation frequency,exacerbation interval,airway resistance(Raw),airway conductance(Gaw),lung function indica-tors[forced vital capacity(FVC),peak expiratory flow(PEF),and forced expiratory volume in 1 second(FEV1)],cardiac function indicators[left ventricular ejection time(LVET),left pre-ejection period(LPEP),isovolumic contraction time(ICT)],and airway inflammation indicators[thymic stromal lymphopoietin(TSLP),serum eosinophil cationic protein(ECP),and fractional exhaled nitric oxide(FeNO)]were compared before and after treatment.Adverse reactions were also compared between the two groups.Results The overall response rate in the observation group was significantly higher than that in the control group(95.83％vs.83.33％;P＜0.05).After treatment,both groups showed a significant reduction in acute exacerbation frequency and Raw(P＜0.05),with the observation group showing significantly lower values than the control group(P＜0.05).The exacerbation interval and Gaw significantly increased in both groups(P＜0.05),with the observation group showing significantly higher values than the control group(P＜0.05).FVC,PEF,and FEV1 significant-ly increased in both groups after treatment(P＜0.05),with the observation group showing significantly higher values than the control group(P＜0.05).LVET significantly increased in both groups after treatment(P＜0.05),with the observa-tion group showing significantly higher values than the control group(P＜0.05),while LPEP and ICT significantly de-creased,with the observation group showing significantly lower values than the control group(P＜0.05).After treatment,TSLP,ECP,and FeNO significantly decreased in both groups(P＜0.05),with the observation group showing significantly lower values than the control group(P＜0.05).No significant difference was noted in the incidence of adverse reactions be-tween the two groups during the treatment period(P＞0.05).Conclusion Tiotropium bromide inhalation powder combined with salmeterol/fluticasone significantly promotes clinical efficacy,cardiac and pulmonary function,and reduces airway in-flammation in elderly ACOS patients,with good safety.
万方数据
维普
